

ASX Announcement**30 August 2019****Non Renounceable Rights Issue
Results and Shortfall Notification**

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, advises that its partially underwritten non-renounceable rights issue of one New Share for every six shares held, at an issue price of \$0.08 closed as scheduled on 27 August 2019.

Regeneus advises that it received valid acceptances for 7,751,973 New Shares (approx. \$620,000), with a shortfall remaining of 31,937,872 New Shares.

New Shares associated with the acceptances above are scheduled to be issued to shareholders on Tuesday, 3 September 2019.

The shortfall of 31,937,872 New Shares is partially underwritten to the extent of 22,500,000 New Shares (\$1,800,000) by directors. Of this underwritten amount \$1,400,000 will be applied to repayment of existing loan funding provided to Regeneus by the directors. The underwriting arrangements are further described in Regeneus' announcement released on 1 August 2019, and also in Section 1.6 of the Entitlement Booklet.

New Shares associated with the underwriting above are also scheduled to be issued to the underwriters on Tuesday, 3 September 2019.

The shortfall following the underwriting is 9,437,872 New Shares (**Shortfall Shares**). The directors of Regeneus reserve the right, subject to the requirements of the Corporations Act and the ASX Listing Rules, to place any Shortfall Shares within 3 months of the closing date at the directors' discretion and at a price not less than the Offer Price.

ENDS

About Regeneus Ltd

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

<http://www.regeneus.com.au>

Contact for further information:**Investors**

Sandra McIntosh

Company Secretary and Investor Relations

Regeneus Ltd

T: +61 2 9499 8010

E: investors@regeneus.com.au